BioPharma Resources

Drug Trial Radar · NCT05144841

A Study to Evaluate Zilovertamab Vedotin (MK-2140) for Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL) (MK-2140-004)

A Phase 2 Open-label Clinical Study to Evaluate the Efficacy and Safety of Zilovertamab Vedotin (MK-2140) in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (waveLINE-004)

Last checked: Nov 19, 2026Latest source record: May 28, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

140

Actual

Start

Jan 8, 2022

Primary completion

Apr 21, 2026

Study completion Apr 21, 2026

Sponsor

Lead sponsor
Merck Sharp & Dohme LLCMerck & Co. (MRK)
Sponsor type
Industry
First posted
Dec 3, 2021

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Non randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to evaluate zilovertamab vedotin with respect to objective response rate and duration of response per Lugano Response Criteria as assessed by blinded independent central review (BICR). Safety and tolerability will also be evaluated in this Phase 2, single arm, interventional study.

Conditions

  • Relapsed or Refractory Diffuse Large B-Cell Lymphoma

Interventions

  • Zilovertamab vedotinBiological

    IV infusion

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Objective Response Rate (ORR) per Lugano Response CriteriaTime frame: Up to approximately 50 months

Locations

71 sites in 17 countries. Site status is shown where the registry gives one.

  • St. Joseph Hospital-The Center for Cancer Prevention and Treatment ( Site 0229)

    Orange, California

  • Innovative Clinical Research Institute ( Site 0202)

    Whittier, California

  • Georgetown University Medical Center ( Site 0204)

    Washington D.C., District of Columbia

  • Northside Hospital ( Site 0206)

    Atlanta, Georgia

  • University of Chicago Medical Center ( Site 0207)

    Chicago, Illinois

  • Franciscan St. Francis Health ( Site 0225)

    Indianapolis, Indiana

  • University of Maryland-Greenebaum Comprehensive Cancer Center ( Site 0211)

    Baltimore, Maryland

  • Massachusetts General Hospital-Cancer Center Protocol Office ( Site 0203)

    Boston, Massachusetts

  • University of Michigan ( Site 0200)

    Ann Arbor, Michigan

  • Karmanos Cancer Institute ( Site 0216)

    Detroit, Michigan

  • Saint Louis University Cancer Center ( Site 0209)

    St Louis, Missouri

  • Atlantic Health System Morristown Medical Center ( Site 0213)

    Morristown, New Jersey

  • New York Medical College ( Site 0215)

    Valhalla, New York

  • University of Cincinnati Medical Center-University of Cincinnati Cancer Center ( Site 0217)

    Cincinnati, Ohio

  • University Hospitals Cleveland Medical Center ( Site 0222)

    Cleveland, Ohio

  • The James Cancer Hospital and Solove Research Institute at The Ohio State University Comprehensive C

    Columbus, Ohio

  • AHN West Penn Hospital ( Site 0212)

    Pittsburgh, Pennsylvania

  • Avera Cancer Institute- Research ( Site 0233)

    Sioux Falls, South Dakota

  • MEDICAL COLLEGE OF WISCONSIN ( Site 0234)

    Milwaukee, Wisconsin

  • Princess Margaret Cancer Centre-Division of Medical Oncology and Hematology ( Site 0100)

    Toronto, Ontario, Canada

  • James Lind Centro de Investigación del Cáncer ( Site 2705)

    Temuco, Araucania, Chile

  • Clínica Alemana de Santiago ( Site 2704)

    Santiago, Region M. de Santiago, Chile

  • Beijing Cancer hospital ( Site 2900)

    Beijing, Beijing Municipality, China

  • SUN YAT-SEN UNIVERSITY CANCER CENTRE-Internal Medicine ( Site 2907)

    Guangzhou, Guangdong, China

  • Henan Cancer Hospital-hematology department ( Site 2903)

    Zhengzhou, Henan, China

  • Wuhan Union Hospital ( Site 2906)

    Wuhan, Hubei, China

  • Hunan Cancer Hospital ( Site 2905)

    Changsha, Hunan, China

  • The First Hospital of Jilin University-Hematology ( Site 2910)

    Changchun, Jilin, China

  • Fudan University Shanghai Cancer Center ( Site 2908)

    Shanghai, Shanghai Municipality, China

  • Shanghai East Hospital ( Site 2902)

    Shanghai, Shanghai Municipality, China

  • West China Hospital of Sichuan University-Head and Neck Oncology ( Site 2911)

    Chengdu, Sichuan, China

  • Tianjin Medical University Cancer Institute and Hospital-lymphoma ( Site 2901)

    Tianjin, Tianjin Municipality, China

  • The First Affiliated Hospital, Zhejiang University-Bone marrow transplant centre ( Site 2912)

    Hangzhou, Zhejiang, China

  • Vseobecna fakultni nemocnice v Praze-I. Interní klinika - klinika hematologie ( Site 0801)

    Prague, Czechia

  • Fakultní nemocnice Brno Bohunice-Interni hematologicka a onkologicka klinika ( Site 0800)

    Brno, Brno-mesto, Czechia

  • North Estonia Medical Centre Foundation ( Site 0900)

    Tallinn, Harju, Estonia

  • Pitie Salpetriere University Hospital-Clinical haematology ( Site 1000)

    Paris, France

  • Centre Hospitalier de la Côte Basque ( Site 1002)

    Bayonne, Aquitaine, France

  • Evangelismos General Hospital of Athens ( Site 1214)

    Athens, Attica, Greece

  • General Hospital of Athens "Laiko"-Hematology Department ( Site 1213)

    Athens, Attica, Greece

Showing 40 of 71 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.